Zealand Pharma reports completion of ...

Zealand Pharma reports completion of the second and pivotal Phase 3...

Zealand Pharma reports completion of the second and pivotal Phase 3 trial with dasiglucagon for the treatment of severe hypoglycemia Last patient visit concluded in the multinational pivotal Phase 3 trial ahead of previous guidance, with key results now expected in Q3 2018, Dasiglucagon is a potential first-in-class soluble glucagon analog in a ready-to-use rescue pen, the HypoPal A , to treat severe hypoglycemia The first Phase 3 trial with dasiglucagon for treatment of severe hypoglycemia was reported to have successfully met its primary objective in Q1 2018 Copenhagen, Denmark, May 28, 2018 - Zealand Pharma announces that all subjects have been enrolled and dosed in the second and pivotal Phase 3 trial to confirm the clinical efficacy and safety of dasiglucagon for the rescue treatment of severe hypoglycemia in patients with type 1 diabetes.

Start the conversation, or Read more at GlobeNewswire.